Sandy Macrae, Sangamo CEO
Novartis turns to Sangamo with a $795M-plus deal aimed at using zinc finger tech for the neuro pipeline
When Novartis recruited Ricardo Dolmetsch from Stanford to lead its neuroscience group, great emphasis was placed on decoding genomics and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
